356 related articles for article (PubMed ID: 20479404)
1. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
Gururangan S; Chi SN; Young Poussaint T; Onar-Thomas A; Gilbertson RJ; Vajapeyam S; Friedman HS; Packer RJ; Rood BN; Boyett JM; Kun LE
J Clin Oncol; 2010 Jun; 28(18):3069-75. PubMed ID: 20479404
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.
Gururangan S; Fangusaro J; Poussaint TY; McLendon RE; Onar-Thomas A; Wu S; Packer RJ; Banerjee A; Gilbertson RJ; Fahey F; Vajapeyam S; Jakacki R; Gajjar A; Goldman S; Pollack IF; Friedman HS; Boyett JM; Fouladi M; Kun LE
Neuro Oncol; 2014 Jan; 16(2):310-7. PubMed ID: 24311632
[TBL] [Abstract][Full Text] [Related]
3. Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study.
Gururangan S; Fangusaro J; Young Poussaint T; Onar-Thomas A; Gilbertson RJ; Vajapeyam S; Gajjar A; Goldman S; Friedman HS; Packer RJ; Boyett JM; Kun LE; McLendon R
Neuro Oncol; 2012 Nov; 14(11):1404-12. PubMed ID: 23019233
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).
Fangusaro J; Gururangan S; Poussaint TY; McLendon RE; Onar-Thomas A; Warren KE; Wu S; Packer RJ; Banerjee A; Gilbertson RJ; Jakacki R; Gajjar A; Goldman S; Pollack IF; Friedman HS; Boyett JM; Kun LE; Fouladi M
Cancer; 2013 Dec; 119(23):4180-7. PubMed ID: 24104527
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: case report.
Torcuator R; Zuniga R; Loutfi R; Mikkelsen T
J Neurooncol; 2009 Jul; 93(3):409-12. PubMed ID: 19139822
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors.
Okada K; Yamasaki K; Tanaka C; Fujisaki H; Osugi Y; Hara J
Jpn J Clin Oncol; 2013 Nov; 43(11):1073-9. PubMed ID: 24002900
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
Vredenburgh JJ; Desjardins A; Herndon JE; Dowell JM; Reardon DA; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Wagner M; Bigner DD; Friedman AH; Friedman HS
Clin Cancer Res; 2007 Feb; 13(4):1253-9. PubMed ID: 17317837
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
Desjardins A; Reardon DA; Herndon JE; Marcello J; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Sampson J; Bailey L; Bigner DD; Friedman AH; Friedman HS; Vredenburgh JJ
Clin Cancer Res; 2008 Nov; 14(21):7068-73. PubMed ID: 18981004
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab in recurrent high-grade pediatric gliomas.
Narayana A; Kunnakkat S; Chacko-Mathew J; Gardner S; Karajannis M; Raza S; Wisoff J; Weiner H; Harter D; Allen J
Neuro Oncol; 2010 Sep; 12(9):985-90. PubMed ID: 20363768
[TBL] [Abstract][Full Text] [Related]
10. Patterns of progression in pediatric patients with high-grade glioma or diffuse intrinsic pontine glioma treated with Bevacizumab-based therapy at diagnosis.
Salloum R; DeWire M; Lane A; Goldman S; Hummel T; Chow L; Miles L; Sutton M; Stevenson C; Fouladi M; Leach J
J Neurooncol; 2015 Feb; 121(3):591-8. PubMed ID: 25433556
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab-containing regimen in relapsed/progressed brain tumors: a single-institution experience.
Schiavetti A; Varrasso G; Mollace MG; Dominici C; Ferrara E; Papoff P; Di Biasi C
Childs Nerv Syst; 2019 Jun; 35(6):1007-1012. PubMed ID: 30903281
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
Sathornsumetee S; Desjardins A; Vredenburgh JJ; McLendon RE; Marcello J; Herndon JE; Mathe A; Hamilton M; Rich JN; Norfleet JA; Gururangan S; Friedman HS; Reardon DA
Neuro Oncol; 2010 Dec; 12(12):1300-10. PubMed ID: 20716591
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours.
Poulsen HS; Grunnet K; Sorensen M; Olsen P; Hasselbalch B; Nelausen K; Kosteljanetz M; Lassen U
Acta Oncol; 2009; 48(1):52-8. PubMed ID: 19031176
[TBL] [Abstract][Full Text] [Related]
14. Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis.
Xu T; Chen J; Lu Y; Wolff JE
BMC Cancer; 2010 Jun; 10():252. PubMed ID: 20525214
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Vredenburgh J; Rich JN; Gururangan S; Badruddoja M; Herndon JE; Dowell JM; Friedman AH; Friedman HS
Cancer; 2005 Jan; 103(2):329-38. PubMed ID: 15558802
[TBL] [Abstract][Full Text] [Related]
16. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan.
Packer RJ; Jakacki R; Horn M; Rood B; Vezina G; MacDonald T; Fisher MJ; Cohen B
Pediatr Blood Cancer; 2009 Jul; 52(7):791-5. PubMed ID: 19165892
[TBL] [Abstract][Full Text] [Related]
17. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors.
Bokstein F; Shpigel S; Blumenthal DT
Cancer; 2008 May; 112(10):2267-73. PubMed ID: 18327820
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.
Møller S; Grunnet K; Hansen S; Schultz H; Holmberg M; Sorensen M; Poulsen HS; Lassen U
Acta Oncol; 2012 Jul; 51(6):797-804. PubMed ID: 22548369
[TBL] [Abstract][Full Text] [Related]
19. Confirmation of Bevacizumab Activity, and Maintenance of Efficacy in Retreatment After Subsequent Relapse, in Pediatric Low-grade Glioma.
Kalra M; Heath JA; Kellie SJ; Dalla Pozza L; Stevens MM; Swamy S; McCowage GB
J Pediatr Hematol Oncol; 2015 Aug; 37(6):e341-6. PubMed ID: 26056795
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS
Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
